User profiles for Cathy Rowe
 | Cathy RoweHead of Vaccine Assays & Immune Response Verified email at ukhsa.gov.uk Cited by 2407 |
Immune boosting by B. 1.1. 529 (Omicron) depends on previous SARS-CoV-2 exposure
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
[HTML][HTML] Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. …
global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. …
[HTML][HTML] Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals
…, A Lloyd, I Damon, T Brooks, R Vipond, C Rowe… - Nature …, 2023 - nature.com
In early 2022, a cluster of monkeypox virus (MPXV) infection (mpox) cases were identified
within the UK with no prior travel history to MPXV-endemic regions. Subsequently, case …
within the UK with no prior travel history to MPXV-endemic regions. Subsequently, case …
Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: from utility to prediction
…, P Simmonds, S Williams, EM Bentley, C Rowe… - …, 2021 - Wiley Online Library
Background Convalescent plasma (CP) therapy for coronavirus disease (COVID‐19) provides
virus‐neutralizing antibodies that may ameliorate the outcome of severe acute respiratory …
virus‐neutralizing antibodies that may ameliorate the outcome of severe acute respiratory …
[HTML][HTML] Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis
Background Few studies have compared SARS-CoV-2 vaccine immunogenicity by ethnic
group. We sought to establish whether cellular and humoral immune responses to SARS-CoV-…
group. We sought to establish whether cellular and humoral immune responses to SARS-CoV-…
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P. 1 Brazilian variant
Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have
received priority consideration for COVID-19 vaccination. However, vaccine responses are …
received priority consideration for COVID-19 vaccination. However, vaccine responses are …
[HTML][HTML] Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in …
Background In response to a national mpox (formerly known as monkeypox) outbreak in
England, children exposed to a confirmed mpox case were offered modified vaccinia Ankara–…
England, children exposed to a confirmed mpox case were offered modified vaccinia Ankara–…
Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021
The COVID-19 vaccination programme commenced in England on 8th December 2020 primarily
based on age; by 7th March 2021 approximately 93% of the English population aged 70…
based on age; by 7th March 2021 approximately 93% of the English population aged 70…
[HTML][HTML] COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care …
Background COVID-19 vaccines have been shown to be highly effective against hospitalisation
and death following COVID-19 infection. COVID-19 vaccine effectiveness estimates …
and death following COVID-19 infection. COVID-19 vaccine effectiveness estimates …
BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P. 1 Brazilian variant
Background: Age is the major risk factor for mortality after SARS-CoV-2 infection and older
people have received priority consideration for COVID-19 vaccination. However vaccine …
people have received priority consideration for COVID-19 vaccination. However vaccine …
